NASDAQ:LGVN Longeveron (LGVN) Stock Price, News & Analysis $1.23 +0.05 (+4.24%) Closing price 06/6/2025 04:00 PM EasternExtended Trading$1.24 +0.01 (+0.41%) As of 06/6/2025 07:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Longeveron Stock (NASDAQ:LGVN) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Longeveron alerts:Sign Up Key Stats Today's Range$1.18▼$1.2550-Day Range$1.18▼$1.7552-Week Range$0.77▼$6.40Volume91,064 shsAverage Volume2.96 million shsMarket Capitalization$18.36 millionP/E RatioN/ADividend YieldN/APrice Target$8.67Consensus RatingBuy Company OverviewLongeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company's lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors. It is conducting Phase 1, Phase 1/2, Phase 2a, and Phase 2b clinical trials in various indications, such as aging-related frailty, alzheimer's disease, and hypoplastic left heart syndrome. Longeveron Inc. was incorporated in 2014 and is headquartered in Miami, Florida.Read More… Longeveron Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks64th Percentile Overall ScoreLGVN MarketRank™: Longeveron scored higher than 64% of companies evaluated by MarketBeat, and ranked 347th out of 939 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingBuy Consensus RatingLongeveron has received a consensus rating of Buy. The company's average rating score is 3.25, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageLongeveron has only been the subject of 1 research reports in the past 90 days.Read more about Longeveron's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Longeveron are expected to grow in the coming year, from ($3.69) to ($1.42) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Longeveron is -0.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Longeveron is -0.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioLongeveron has a P/B Ratio of 0.46. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Longeveron's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.98% of the float of Longeveron has been sold short.Short Interest Ratio / Days to CoverLongeveron has a short interest ratio ("days to cover") of 2.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Longeveron has recently decreased by 11.20%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldLongeveron does not currently pay a dividend.Dividend GrowthLongeveron does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted3.98% of the float of Longeveron has been sold short.Short Interest Ratio / Days to CoverLongeveron has a short interest ratio ("days to cover") of 2.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Longeveron has recently decreased by 11.20%, indicating that investor sentiment is improving significantly. News and Social Media1.1 / 5News Sentiment-0.08 News SentimentLongeveron has a news sentiment score of -0.08. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.71 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Longeveron this week, compared to 1 article on an average week. Company Ownership1.7 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Longeveron insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $36,740.00 in company stock.Percentage Held by Insiders11.20% of the stock of Longeveron is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 10.01% of the stock of Longeveron is held by institutions.Read more about Longeveron's insider trading history. Receive LGVN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Longeveron and its competitors with MarketBeat's FREE daily newsletter. Email Address LGVN Stock News HeadlinesLongeveron Inc. (NASDAQ:LGVN) Director Sells $13,000.00 in StockJune 3, 2025 | insidertrades.comHere's Why Longeveron (NASDAQ:LGVN) Must Use Its Cash WiselyMay 29, 2025 | finance.yahoo.comMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tariffs just lit the fuse. Millions of investors are blindsided as stocks plunge… but this is only Phase 1. If you're still holding the wrong assets, you could lose 30% or more in the coming weeks.June 7, 2025 | American Alternative (Ad)Longeveron Inc. to Explore Partnership Opportunities for Alzheimer’s Stem Cell Therapy Program at BIO International ConventionMay 22, 2025 | nasdaq.comLongeveron Inc.May 21, 2025 | marketwatch.comLongeveron® to Attend BIO International Convention 2025May 20, 2025 | globenewswire.comLongeveron® Named XPRIZE Healthspan Semifinalist and Top 40 Milestone 1 Award RecipientMay 12, 2025 | globenewswire.comLongeveron Inc. (LGVN) Q1 2025 Earnings Call TranscriptMay 9, 2025 | seekingalpha.comSee More Headlines LGVN Stock Analysis - Frequently Asked Questions How have LGVN shares performed this year? Longeveron's stock was trading at $1.73 at the start of the year. Since then, LGVN stock has decreased by 28.9% and is now trading at $1.23. View the best growth stocks for 2025 here. How were Longeveron's earnings last quarter? Longeveron Inc. (NASDAQ:LGVN) released its quarterly earnings results on Tuesday, November, 12th. The company reported ($0.34) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.53) by $0.19. The business earned $0.77 million during the quarter, compared to analysts' expectations of $0.34 million. Longeveron had a negative trailing twelve-month return on equity of 142.43% and a negative net margin of 967.49%. Read the conference call transcript. When did Longeveron's stock split? Shares of Longeveron reverse split on Wednesday, March 27th 2024. The 1-10 reverse split was announced on Wednesday, March 27th 2024. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, March 27th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. When did Longeveron IPO? Longeveron (LGVN) raised $30 million in an IPO on Friday, February 12th 2021. The company issued 2,700,000 shares at $10.00-$12.00 per share. Kingswood Capital Markets and Alexander Capital L.P. acted as the underwriters for the IPO. Who are Longeveron's major shareholders? Top institutional investors of Longeveron include R Squared Ltd (0.16%). Insiders that own company stock include Joshua Hare, Rock Soffer, Khoso Baluch, Mohamed Wa'el Ahmed Hashad, James Clavijo, Jeffrey Pfeffer and Cathy Ross. View institutional ownership trends. How do I buy shares of Longeveron? Shares of LGVN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Longeveron own? Based on aggregate information from My MarketBeat watchlists, some other companies that Longeveron investors own include Zomedica (ZOM), Jumia Technologies (JMIA), Nano Dimension (NNDM), NIO (NIO), AST SpaceMobile (ASTS), Virgin Galactic (SPCE) and Phunware (PHUN). Company Calendar Last Earnings11/12/2024Today6/07/2025Next Earnings (Estimated)8/13/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:LGVN CIK1721484 Webwww.longeveron.com Phone305-302-7158FaxN/AEmployees20Year FoundedN/APrice Target and Rating Average Stock Price Target$8.67 High Stock Price Target$10.00 Low Stock Price Target$6.00 Potential Upside/Downside+604.6%Consensus RatingBuy Rating Score (0-4)3.25 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($6.28) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$21.41 million Net Margins-967.49% Pretax Margin-967.49% Return on Equity-142.43% Return on Assets-100.84% Debt Debt-to-Equity RatioN/A Current Ratio7.67 Quick Ratio7.67 Sales & Book Value Annual Sales$2.23 million Price / Sales8.25 Cash FlowN/A Price / Cash FlowN/A Book Value$2.68 per share Price / Book0.46Miscellaneous Outstanding Shares14,928,000Free Float12,000,000Market Cap$18.36 million OptionableNot Optionable Beta0.22 Elon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free Report This page (NASDAQ:LGVN) was last updated on 6/7/2025 by MarketBeat.com Staff From Our PartnersAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredTrump’s Wealth Reset: Could You Be The First Beneficiary?Trump's Reset Can Give Birth To America's Greatest Era Yet A 90-Year cycle may end soon, creating real weal...American Hartford Gold | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredHere’s How to Claim Your Stake in Elon’s Private Company, xAIEven though xAI is a private company, tech legend and angel investor Jeff Brown found a way for everyday folks...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Longeveron Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Longeveron With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.